About GHRS

Founded: 2018
Employees: 73
CEO: Velichka Valcheva
WebsiteView website: www.ghres.com

GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company’s lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.

Recent GHRS News & Updates

Live News • May 17

GH Research Advances Depression Drug Toward Phase 3 Backed by Strong Cash and Capital Moves

GH Research published Phase 2b TRD data for lead candidate GH001 in JAMA Psychiatry, reporting Day 8 remission rates between 53.9% and 63.6%. The company has selected doses for a planned global Phase 3 program targeted to start in late 2026. The company reported a Q1 2026 net loss that was wider than some analyst expectations as research, development and professional expenses related to its psychiatric pipeline increased. It maintained a cash balance of US$267.3 million as of March 31, 2026, and raised an additional US$111.2 million in April. GH Research filed an F-3 shelf to register up to US$400 million of securities and entered an at-the-market equity offering of up to US$200 million. The company also reported a 2025 net loss of US$48.3 million with an accumulated deficit of US$154.4 million, and set its 2026 AGM for June 25. The combination of positive mid-stage clinical data, an advancing late-stage trial plan and multiple capital-raising tools indicates a company focused on funding an intensive clinical program in treatment-resistant depression and related indications. Investors need to weigh the strengthened liquidity against ongoing losses, clinical and regulatory risk, potential dilution from the shelf and ATM programs, and the history of the prior FDA clinical hold that was lifted in December 2025.

Recent updates

No updates

GH Research PLC Stock Price

GHRS Share Price Performance

GHRS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

GH Research PLC Key Details

About GHRS

Recent GHRS News & Updates

Insufficient new directors

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research Advances Depression Drug Toward Phase 3 Backed by Strong Cash and Capital Moves

Recent updates

GH Research PLC Competitors

Praxis Precision Medicines

ICON

Krystal Biotech

Tempus AI